This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis. Thank you for everything you do.

      Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    SEDAN Score for Post-tPA Hemorrhage

    Predicts risk of Symptomatic Intracerebral Hemorrhage (sICH) after tPA.

    INSTRUCTIONS

    Applies to patients receiving tPA within 4.5 hours; does not apply to patients receiving endovascular treatment.

    When to Use
    Pearls/Pitfalls
    Why Use
    • Providing actual estimates of risk of tPA to patients and their family members.
    • Weighing risk of benefit and risk of harm in minor or severe strokes.
    • The SEDAN Score predicts risk of post-tPA hemorrhage.
    • tPA hemorrhage risk varies greatly, so its developers wanted to predict low- and high-risk patients.
    • The endpoint, “Symptomatic Intracerebral Hemorrhage” varies greatly from trial to trial depending on definition, making it difficult to compare outcomes.
    • The HAT Score also predicts risk of sICH with fewer variables.
    • The THRIVE Score predicts chance of good outcome after stroke (even without tPA) and does not require imaging variables.

    Points to Consider

    • Patients in this score did not receive endovascular therapy.
    • sICH increases mortality dramatically.
    • tPA risks and benefits should be very clearly discussed and documented with patients and family members.

    With rates of sICH varying widely, the SEDAN Score can help predict which patients will be at low or high risk to go on to have sICH, which increases mortality dramatically.

    <145 mg/dL (8.1 mmol/L)
    0
    145-216 mg/dL (8.1–12.0 mmol/L)
    +1
    >216 mg/dL (12.0 mmol/L)
    +2
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Daniel Strbian

    About the Creator

    Daniel Strbian, MD, PhD, is a practicing neurologist at the University of Helsinki Central Hospital in Finland. He is an active researcher in the field of ischemic stroke.

    To view Dr. Daniel Strbian's publications, visit PubMed

    Content Contributors
    About the Creator
    Dr. Daniel Strbian
    Content Contributors